Supernus Pharmaceuticals Inc

S49

Company Profile

  • Business description

    Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

  • Contact

    9715 Key West Avenue
    RockvilleMD20850
    USA

    T: +1 301 838-2500

    E: [email protected]

    https://www.supernus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    674

Stocks News & Analysis

stocks

Have the 3 biggest losers of the ASX 200 fallen too far?

Finding value in some of the ASX’s worst recent performers.
stocks

Rethinking the way we invest in Aussie tech

Investing in Tech companies has many caveats from traditional investing. Let’s dive into how you can gauge the true profitability of a tech company.
stocks

Undervalued ASX listed payment provider

Strong start to the new fiscal year.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,884.7038.30-0.43%
CAC 408,122.7123.240.29%
DAX 4023,836.7968.830.29%
Dow JONES (US)47,716.42289.300.61%
FTSE 1009,720.5126.580.27%
HKSE25,967.11108.220.42%
NASDAQ23,365.69151.000.65%
Nikkei 22549,465.73788.18-1.57%
NZX 50 Index13,446.3642.79-0.32%
S&P 5006,849.0936.480.54%
S&P/ASX 2008,585.1029.00-0.34%
SSE Composite Index3,893.785.190.13%

Market Movers